NZ745023A - Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses - Google Patents

Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses

Info

Publication number
NZ745023A
NZ745023A NZ745023A NZ74502317A NZ745023A NZ 745023 A NZ745023 A NZ 745023A NZ 745023 A NZ745023 A NZ 745023A NZ 74502317 A NZ74502317 A NZ 74502317A NZ 745023 A NZ745023 A NZ 745023A
Authority
NZ
New Zealand
Prior art keywords
trifluoroacetate salt
crystalline form
tlr7 agonist
preparation methods
methods
Prior art date
Application number
NZ745023A
Other languages
English (en)
Inventor
Zhaozhong Ding
Ling Yang
Fei Sun
Yinghu Hu
Yilong Zhou
Zheng Wang
Rui Zhao
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of NZ745023A publication Critical patent/NZ745023A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
NZ745023A 2016-02-05 2017-02-04 Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses NZ745023A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610081899.3A CN107043377A (zh) 2016-02-05 2016-02-05 一种tlr7激动剂的三氟乙酸盐、晶型b及其制备方法、药物组合物和用途
PCT/CN2017/072894 WO2017133687A1 (zh) 2016-02-05 2017-02-04 一种tlr7激动剂的三氟乙酸盐、晶型b、制备方法和用途

Publications (1)

Publication Number Publication Date
NZ745023A true NZ745023A (en) 2022-09-30

Family

ID=59500539

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ745023A NZ745023A (en) 2016-02-05 2017-02-04 Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses

Country Status (23)

Country Link
US (1) US10683296B2 (enExample)
EP (1) EP3412674B1 (enExample)
JP (1) JP6877450B2 (enExample)
KR (1) KR102393281B1 (enExample)
CN (2) CN107043377A (enExample)
AR (1) AR107550A1 (enExample)
AU (1) AU2017214135B2 (enExample)
CA (1) CA3013521C (enExample)
CL (1) CL2018002101A1 (enExample)
DK (1) DK3412674T3 (enExample)
EA (1) EA037048B1 (enExample)
ES (1) ES2834304T3 (enExample)
HU (1) HUE052210T2 (enExample)
IL (1) IL260981B (enExample)
MX (1) MX374300B (enExample)
MY (1) MY198137A (enExample)
NZ (1) NZ745023A (enExample)
PH (1) PH12018501641B1 (enExample)
SG (1) SG11201806688QA (enExample)
TW (1) TWI778952B (enExample)
UA (1) UA121276C2 (enExample)
WO (1) WO2017133687A1 (enExample)
ZA (1) ZA201805240B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107043380A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种tlr7激动剂的马来酸盐、其晶型c、晶型d、晶型e、制备方法和用途
CN107043378A (zh) * 2016-02-05 2017-08-15 正大天晴药业集团股份有限公司 一种吡咯并[3,2-d]嘧啶类化合物的制备方法及其中间体
EP3414239A2 (en) 2016-02-05 2018-12-19 Denali Therapeutics Inc. Inhibitors of receptor-interacting protein kinase 1
JP7385602B2 (ja) * 2018-05-25 2023-11-22 チア タイ ティエンチン ファーマシューティカル グループ カンパニー リミテッド 肺癌を治療するためのtlr7アゴニストおよびその医薬の組み合わせ
JP7287708B2 (ja) 2019-02-08 2023-06-06 プロジェニア インコーポレイテッド Toll-like受容体7または8アゴニストとコレステロールの結合体およびその用途
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
EP4194010A4 (en) 2020-08-04 2025-03-26 Progeneer Inc. Conjugate of a functional drug and a toll-like receptor 7 or 8 agonist with a temporarily inactivated drug site, and use thereof
EP4194006A4 (en) 2020-08-04 2024-12-04 Progeneer Inc. mRNA VACCINE WITH AN ADJUVANT CAPABLE OF KINETIC CONTROL
EP4463229A1 (en) 2022-01-12 2024-11-20 Denali Therapeutics Inc. Crystalline forms of (s)-5-benzyl-n-(5-methyl-4-oxo-2, 3,4,5- tetrahydropyrido [3,2-b] [l,4]oxazepin-3-yl)-4h-l,2,4-triazole-3-carboxamide
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3376479B2 (ja) * 1991-08-12 2003-02-10 武田薬品工業株式会社 縮合ピリミジン誘導体、その製造法および用途
BRPI0923305B1 (pt) 2008-12-09 2019-01-22 Gilead Sciences Inc moduladores de receptores toll-like, seu uso e composição farmacêutica que os compreende
CA2826295C (en) * 2011-02-04 2020-10-20 Duquesne University Of The Holy Spirit Bicyclic and tricyclic pyrimidine tyrosine kinase inhibitors with antitubulin activity and methods of treating a patient
WO2013103967A1 (en) * 2012-01-05 2013-07-11 Northeastern University Allosteric modulators of cb1 cannabinoid receptors
PT2906563T (pt) * 2012-10-10 2018-05-23 Janssen Sciences Ireland Uc Derivados de pirrolo[3,2-d]pirimidina para o tratamento de infeções virais e outras doenças
EP2922550B1 (en) * 2012-11-20 2017-04-19 Glaxosmithkline LLC Novel compounds
PT3137470T (pt) * 2014-05-01 2021-06-24 Novartis Ag Compostos e composições como agonistas do recetor tipo toll 7
KR20160144399A (ko) * 2014-05-01 2016-12-16 노파르티스 아게 톨-유사 수용체 7 효능제로서의 화합물 및 조성물
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
UA117634C2 (uk) * 2014-08-15 2018-08-27 Чиа Тай Тяньцін Фармасьютикал Ґруп Ко., Лтд. Піролопіримідинові сполуки, що використовуються як агоніст tlr7
CN105732635A (zh) * 2014-12-29 2016-07-06 南京明德新药研发股份有限公司 一类Toll样受体7激动剂

Also Published As

Publication number Publication date
CA3013521C (en) 2022-07-12
US20190031666A1 (en) 2019-01-31
EA037048B1 (ru) 2021-01-29
PH12018501641B1 (en) 2021-03-26
EP3412674B1 (en) 2020-09-16
US10683296B2 (en) 2020-06-16
JP6877450B2 (ja) 2021-05-26
AR107550A1 (es) 2018-05-09
MX2018009503A (es) 2018-12-11
ZA201805240B (en) 2024-09-25
HUE052210T2 (hu) 2021-04-28
BR112018015878A2 (pt) 2018-12-26
AU2017214135B2 (en) 2020-08-13
TW201728591A (zh) 2017-08-16
CN108602833A (zh) 2018-09-28
WO2017133687A1 (zh) 2017-08-10
IL260981B (en) 2022-05-01
JP2019504103A (ja) 2019-02-14
SG11201806688QA (en) 2018-09-27
PH12018501641A1 (en) 2019-06-03
AU2017214135A1 (en) 2018-08-23
EP3412674A1 (en) 2018-12-12
UA121276C2 (uk) 2020-04-27
EP3412674A4 (en) 2019-07-17
ES2834304T3 (es) 2021-06-17
CA3013521A1 (en) 2017-08-10
HK1259182A1 (zh) 2019-11-29
MY198137A (en) 2023-08-07
CL2018002101A1 (es) 2018-12-07
KR102393281B1 (ko) 2022-05-02
CN108602833B (zh) 2020-07-28
KR20180104118A (ko) 2018-09-19
MX374300B (es) 2025-03-06
EA201891772A1 (ru) 2019-01-31
DK3412674T3 (da) 2020-11-09
CN107043377A (zh) 2017-08-15
TWI778952B (zh) 2022-10-01

Similar Documents

Publication Publication Date Title
NZ745023A (en) Tlr7 agonist trifluoroacetate salt and crystalline form b thereof, preparation methods and uses
NZ744884A (en) Tlr7 agonist crystalline form a, preparation method and use thereof
PH12017501061B1 (en) 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
NZ727996A (en) Thieno [3,2-d] pyrimidine, furo [3,2,d] pyrimidine, and pyrrolo [3,2-d] pyrimidines useful for treating respiratory syncytial virus infections
NZ747259A (en) Soluble c5ar antagonists
PH12019500930A1 (en) PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF
TN2018000219A1 (en) Soluble guanylate cyclase stimulators
NZ630800A (en) Methods of preparing substituted nucleotide analogs
WO2014155300A3 (en) Substitued pyrimidine amine derivatives as tak-1 inhibitors
AU2018253590A1 (en) Imidazopyridazine compounds
MD20160053A2 (ro) Derivaţi ai purinei 2,6-substituite şi utilizarea acestora în tratamentul tulburărilor proliferative
MX2018009502A (es) Metodo para preparar compuesto de pirrolo[3,2-d]pirimidina y sus intermediarios.
MY191352A (en) Aldosterone synthase inhibitors
MX372682B (es) Procesos e intermediarios para preparar dialcano eteres terminados con acido a, ?-dicarboxilico.
WO2015068175A3 (en) An improved process for the preparation of pazopanib or a pharmaceutically acceptable salt thereof
PH12018502246A1 (en) Substituted fused pyrimidinone compounds
TW201613921A (en) Serine derivatives as ghrelin receptor agonists
NZ724424A (en) Pyrimidine derivatives for the treatment of bacterial diseases
WO2015102017A8 (en) Processes for the preparation of lorcaserin
MY197130A (en) Tlr7 agonist crystalline form a, preparation method and use thereof
CO2017002070A2 (es) Un proceso para la preparación de derivados de 3-fenil/heteroaril-6-fenoxi-8-alquilamino-imidazo[1,2-b] piridazina
IN2013CH05870A (enExample)
UA80534U (uk) 1-[[3-(4,7-ДИГІДРО-1-МЕТИЛ-7-ОКСО-3-ПРОПІЛ-1Н-ПІРАЗОЛО[4,3-d]ПІРИМІДИН-5-ІЛ)-4-ЕТОКСИФЕНІЛ]СУЛЬФОНІЛ]-4-МЕТИЛПІПЕРАЗИН ТА ЙОГО ФАРМАЦЕВТИЧНО ПРИЙНЯТНІ СОЛІ

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2025 BY CPA GLOBAL

Effective date: 20231221

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 04 FEB 2026 BY ABHISHEK KUMAR - CPA-PTO PAYMENTS

Effective date: 20241219